Kiniksa Pharmaceuticals International
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 41 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.9 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 64.88% +1.92pp
- Institutions
- 365 +41
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Sanjiv Patel | Chairperson & CEO | 2.11% |
| John Paolini | Chief Medical Officer | 0.09% |
| Eben Tessari | Consultant | 0.03% |
| Michael Megna | Chief Accounting Officer | 0.04% |
| Richard Levy | Independent Director | 0.03% |
| Mark Ragosa | Chief Financial Officer | 0.03% |
| Kimberly Popovits | Independent Director | 0.02% |
| Ross Moat | President, Executive VP, COO & Principal Operating Officer | 0.02% |
| Tracey McCain | Independent Director | 0.02% |
| Thomas Malley | Independent Director | 0.02% |
| Felix Baker | Lead Independent Director | 0.02% |
| Julian Baker | -- | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | Michael Megna | Chief Accounting Officer | Derivative Exercise and Sale | -11,280 | $17.76–98.54 |
| 2026-11-03 | Sanjiv Patel | Chairperson & CEO | Automatic Disposition | -5,537 | $96.05 |
| 2026-11-03 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Sale | -145,763 | $17.92–96.05 |
| 2026-11-02 | Sanjiv Patel | Chairperson & CEO | Open Market Disposition | -171,257 | $91.83–98.16 |
| 2026-11-02 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Sale | -231,237 | $8.83–93.53 |
| 2026-11-01 | John Paolini | Chief Medical Officer | Derivative Exercise and Sale | -96,000 | $17.92–97.77 |
| 2026-11-01 | Mark Ragosa | Chief Financial Officer | Derivative Exercise and Sale | -36,783 | $10.76–94.01 |
| 2026-11-01 | Ross Moat | President, Executive VP, COO & Principal Operating Officer | Derivative Exercise and Sale | -97,572 | $10.76–96.03 |
| 2026-10-29 | Sanjiv Patel | Chairperson & CEO | Intent to Sell (Form 144) | -553,794 | $93.12 |
| 2026-10-29 | John Paolini | Chief Medical Officer | Intent to Sell (Form 144) | -96,000 | $93.02 |
| 2026-10-29 | Michael Megna | Chief Accounting Officer | Automatic Disposition | -16,365 | $94.20–97.74 |
| 2026-10-29 | Michael Megna | Chief Accounting Officer | Derivative Exercise and Sale | -19,895 | $10.76–94.20 |
| 2026-10-29 | Ross Moat | President, Executive VP, COO & Principal Operating Officer | Automatic Disposition | -6,013 | $96.03–97.76 |
| 2026-09-02 | Michael Megna | Chief Accounting Officer | Derivative Exercise and Sale | -10,131 | $79.28–80.30 |
| 2026-09-02 | Michael Megna | Chief Accounting Officer | Intent to Sell (Form 144) | -4,600 | $80.30 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Sale | -15,144 | $79.28 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Other Derivative Acquisition | +30,050 | -- |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Other Derivative Acquisition | +120,150 | $79.28 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Retained | +16,174 | -- |
| 2026-08-31 | John Paolini | Chief Medical Officer | Derivative Exercise and Sale | -4,029 | $79.28 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Kiniksa Pharmaceuticals International discussion 0 comments